SGLT2 inhibitors superior to GLP-1 receptor agonists for lowering HF hospitalizations: Study
Written By : Dr. Shravani Dali
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-09-29 05:15 GMT | Update On 2021-09-29 05:21 GMT
Advertisement
Patients with diabetes mellitus taking an SGLT2 inhibitor have a lower risk for hospitalization for Heart Failure compared with those taking a GLP-1 receptor agonist, according to a study published in the Annals of Internal Medicine.
Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.